Amicus Therapeutics (FOLD) News Today $6.03 -0.14 (-2.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.03 0.00 (0.00%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from AnalystsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been given an average rating of "Moderate Buy" by the ten ratings firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to theJune 14 at 3:28 AM | marketbeat.comIn NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House RaidJune 13 at 6:23 PM | globenewswire.comIn NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection RegimeJune 12 at 4:16 PM | globenewswire.comAmicus Therapeutics: Opportunity Awaits In This Beaten Down PharmaJune 12 at 11:03 AM | seekingalpha.comWedge Capital Management L L P NC Decreases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wedge Capital Management L L P NC lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 23.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 143,778 shares of the biopharmaceutical company's stock after selling 45,007 sJune 11 at 4:37 AM | marketbeat.comZacks Research Has Negative Outlook for FOLD Q2 EarningsJune 7, 2025 | americanbankingnews.comZacks Research Analysts Decrease Earnings Estimates for FOLDAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities research analysts at Zacks Research cut their Q2 2025 earnings per share estimates for Amicus Therapeutics in a report released on Tuesday, June 3rd. Zacks Research analyst R. Department now expects that the biopharmaceutical companJune 6, 2025 | marketbeat.comNew Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and NerveJune 3, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 471,902 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 96.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 958,671 shares of thJune 1, 2025 | marketbeat.comTwo Sigma Advisers LP Buys 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Two Sigma Advisers LP raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 86.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,976 shares of the biopJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Boosts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Two Sigma Investments LP grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 136.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 297,443 shares of the bJune 1, 2025 | marketbeat.comMillennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Millennium Management LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 457,014 shares of the biopharmaceutical company's stoMay 31, 2025 | marketbeat.comAmicus Therapeutics to Present at Upcoming Investor Conferences in June 2025May 30, 2025 | globenewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Decreased by Voloridge Investment Management LLCVoloridge Investment Management LLC reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 31.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 880,112 sharMay 27, 2025 | marketbeat.comWoodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Woodline Partners LP lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 70.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 301,335 shares of the biopharmaceutical company's stock afteMay 27, 2025 | marketbeat.comMan Group plc Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Man Group plc trimmed its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 92.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,441 shares of the biopharmaceutiMay 27, 2025 | marketbeat.comNeo Ivy Capital Management Acquires 329,959 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Neo Ivy Capital Management raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 501.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 395,745 shares of the biopharmaceutical company's stock afteMay 25, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Squarepoint Ops LLCSquarepoint Ops LLC boosted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 113.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,417,152 shares of the biopharmaceutical company's stock aftMay 25, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Cut by Teza Capital Management LLCTeza Capital Management LLC cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 63.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,458 shares of the biopharmaceutical company'sMay 23, 2025 | marketbeat.comNuveen Asset Management LLC Buys 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Nuveen Asset Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,807,420 shares of the biopharmaceutical company's stock afterMay 23, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by AnalystsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have issued a buy ratingMay 22, 2025 | marketbeat.com3,350,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Vestal Point Capital LPVestal Point Capital LP purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,350,0May 21, 2025 | marketbeat.comSovereign s Capital Management LLC Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Sovereign s Capital Management LLC bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 297,830 shares of the biopharmaceutical company's stock, vMay 21, 2025 | marketbeat.comRafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Rafferty Asset Management LLC lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 333,391 shares of the biopharmaMay 21, 2025 | marketbeat.comDeutsche Bank AG Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Deutsche Bank AG grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 822,108 shares of the biopharmaceutical company'sMay 20, 2025 | marketbeat.comProsight Management LP Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Prosight Management LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 920,000 shares of the biopharmaceutical company'sMay 17, 2025 | marketbeat.comJanus Henderson Group PLC Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Janus Henderson Group PLC lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 46.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,395,058 shares of the biopharmaceutical company's stock after selling 2,940,177 sharesMay 17, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 784,376 shares of the biopharmaceutical company's stock after puMay 16, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)D. E. Shaw & Co. Inc. lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 132.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,560,410 shares of the biopharmaceutical company's stock after purchasing an additionalMay 16, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 14.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4May 16, 2025 | marketbeat.comOrbimed Advisors LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Orbimed Advisors LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 300.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,285,400 shares of the biopharmaceuMay 15, 2025 | marketbeat.comIs Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | insidermonkey.comHudson Bay Capital Management LP Purchases 379,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Hudson Bay Capital Management LP boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 26.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,804,800 shares of the biopharmaceutical company's stock after buying aMay 13, 2025 | marketbeat.comNorthern Trust Corp Acquires 187,652 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Northern Trust Corp grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 5.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,371,639 shares of the biopharmaceutical company's stock after acquiring anMay 13, 2025 | marketbeat.comBalyasny Asset Management L.P. Has $8 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Balyasny Asset Management L.P. lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 58.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 849,405 shares of the bioMay 12, 2025 | marketbeat.comBayesian Capital Management LP Acquires 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Bayesian Capital Management LP increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 422.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,900 shares of the biopharmaceuticMay 9, 2025 | marketbeat.comAlgert Global LLC Acquires 165,923 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Algert Global LLC raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 64.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 425,083 shares of the biopharmaceutical company's stockMay 9, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC trimmed its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 32.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 205,702 shares of the biopharmaceutical company's stock aMay 8, 2025 | marketbeat.comAmicus Therapeutics to Present at the Bank of America 2025 Health Care ConferenceMay 7, 2025 | globenewswire.comMarshall Wace LLP Grows Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Marshall Wace LLP boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 254.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,968 shares of the biopharmaceutical companMay 4, 2025 | marketbeat.comVoya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Voya Investment Management LLC trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 52.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 676,353 shares of the biopharmaceuticalMay 2, 2025 | marketbeat.comAmicus Therapeutics revenue misses estimates, stock tumblesMay 1, 2025 | in.investing.comPDT Partners LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)PDT Partners LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 352,498 shares of the biopharmaceutical company's stock after aMay 1, 2025 | marketbeat.comAmicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0. ...May 1, 2025 | gurufocus.comAmicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate UpdatesMay 1, 2025 | globenewswire.comAquatic Capital Management LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Aquatic Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 201.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,414 shares of the biopharmaceutical company's sMay 1, 2025 | marketbeat.comTower Research Capital LLC TRC Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Tower Research Capital LLC TRC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 419.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,075 shaMay 1, 2025 | marketbeat.comDimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United StatesApril 30, 2025 | globenewswire.com38,148 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Dark Forest Capital Management LPDark Forest Capital Management LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 38,148 shares of the biopharmaceutical company's stock, valued at approximately $359,000. OtherApril 30, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from BrokeragesAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy ratingApril 27, 2025 | marketbeat.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.220.88▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼76▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News HALO News MDGL News IONS News ALKS News BCRX News LGND News CLDX News INVA News MNKD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
